Newton Biocapital
Newton Biocapital, established in 2017 and headquartered in Brussels, Belgium, is a venture capital firm specializing in early-stage investments in the biotech and life science sectors. The company focuses on Europe and Japan, supporting promising start-ups and undervalued late-stage projects in the prevention and treatment of chronic diseases. As a lead investor, Newton Biocapital provides not only capital but also expert guidance and coaching to bio-entrepreneurs throughout the development stages of their projects. The firm's investment approach aligns with ESG principles, seeking opportunities that meet the criteria under Article 8 of the SFDR.
Past deals in Belgium
Augustine Therapeutics
Series A in 2025
Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.